Related references
Note: Only part of the references are listed.Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future
Benedicte Caron et al.
JOURNAL OF CROHNS & COLITIS (2021)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease
Parambir S. Dulai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
Constance Chapuis-Biron et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Long-term safety of vedolizumab for inflammatory bowel disease
Edward V. Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Developing a core outcome set for fistulising perianal Crohn's disease
Kapil Sahnan et al.
GUT (2019)
Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the Phase 3b VERSIFY trial
S. Danese et al.
JOURNAL OF CROHNS & COLITIS (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease
Lucie Thomassin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Tim Wyant et al.
JOURNAL OF CROHNS & COLITIS (2016)
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy
Carlos Castaño-Milla et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2014)
Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease
N. A. Yassin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis
Alexander C. Ford et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
Pieter Dewint et al.
GUT (2014)
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease
Krisztina B. Gecse et al.
GUT (2014)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study
S. Schreiber et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study
RL West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)